In addition, we also reported previously that earlier generations of agonistic EphA2-targeting-peptide mimetics can be used as carriers for targeted delivery of chemotherapy to breast [17], pancreatic [15,18], and prostate cancer [19,20,21]. This evidence concerns the gene EPHA2 and Familial prostate cancer.